Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome.
2026. nov. 4.· Expert review of anticancer therapy· PUBMED
Publikáció
Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer.
2026. nov. 2.· Molecular pharmaceutics· PUBMED
Publikáció
High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates.
2026. okt. 24.· Langenbeck's archives of surgery· PUBMED
Vizsgálat
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
2026. okt. 16.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
Nectin-4 and TROP-2 in bladder cancer: biomarkers for targeted therapy.
2026. okt. 15.· Pathobiology : journal of immunopathology, molecular and cellular biology· PUBMED
Publikáció
Prognostic Significance of B7-H3, TROP2, and p16 Expression in Pleural Mesothelioma: Clinicopathological Correlations and Survival Outcomes.
2026. okt. 15.· Journal of clinical medicine· PUBMED
Publikáció
Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
2026. okt. 7.· Cancers· PUBMED
Publikáció
Expression of NECTIN-4 and TROP-2 in Resected Upper Tract Urothelial Carcinoma with and Without Preoperative Chemotherapy.
2026. okt. 6.· European urology open science· PUBMED
Publikáció
Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies.
2026. okt. 6.· Cureus· PUBMED
Vizsgálat
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
2026. okt. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
2026. okt. 1.· PHASE2 · RECRUITING· CTGOV
Publikáció
Multi-parameter optimization of a novel anti-TROP2 MMAE antibody-drug-conjugate for solid tumor therapy.
2026. szept. 30.· Frontiers in oncology· PUBMED
Preprint
Quantitative Systems Pharmacology Model for TROP-2 Targeted Antibody-Drug Conjugate in Triple-Negative Breast Cancer.
2026. szept. 25.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018).
2026. szept. 24.· European journal of cancer (Oxford, England : 1990)· PUBMED
Publikáció
NECTIN4, TROP2 and PDL1 in Breast Cancer: Immunohistochemical Profiling and Clinical Associations.
2026. szept. 22.· International journal of surgical pathology· PUBMED
Publikáció
TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes.
2026. szept. 17.· ESMO gastrointestinal oncology· PUBMED
Publikáció
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.
2026. szept. 13.· Clinical pharmacology and therapeutics· PUBMED
Publikáció
Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma.
2026. szept. 7.· Diagnostics (Basel, Switzerland)· PUBMED
Vizsgálat
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
2026. szept. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Durable Intracranial Response to Sacituzumab Tirumotecan in HER2-Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report.
2026. szept. 1.· Cancer reports (Hoboken, N.J.)· PUBMED
Vizsgálat
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
2026. aug. 31.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
TROP2 NMR Concordance Study
2026. aug. 13.· NA · RECRUITING· CTGOV
Publikáció
Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis.
2026. aug. 13.· Current issues in molecular biology· PUBMED
Publikáció
Adipocyte-derived estrogen signaling influences TROP2 expression in ERα-positive breast cancer.
2026. aug. 12.· Frontiers in endocrinology· PUBMED
Vizsgálat
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
2026. aug. 11.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
TROP-2 and Nectin-4 Expression in Muscle-Invasive Urothelial and Rare Non-Urothelial Bladder Carcinoma: Association with Tumour Stage and Clinical Outcome.
2026. aug. 11.· Cancers· PUBMED
Publikáció
Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.
2026. aug. 7.· Gynecologic oncology· PUBMED
Publikáció
TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome.
2026. aug. 6.· Frontiers in oncology· PUBMED
Publikáció
Prognostic and therapeutic importance of TROP-2 and MUC-1 in non-small cell lung cancer: A systematic review and meta-analysis.
2026. aug. 5.· Biomedical reports· PUBMED
Vizsgálat
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
2026. aug. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV